PIK3CA and pancreatic neoplasm: Whilst some mechanisms of resistance to PI3K inhibitors have been identified such as mitogen-activated protein kinase kinase activation also known as MEK [87,88], other mechanisms of resistance remain elusive in pancreatic cancer.